Epstein-Barr infection: Current treatment options
Author:
- 1 January 2013
- journal article
- review article
- Published by Medknow in Annals of Tropical Medicine and Public Health
- Vol. 6 (1) , 10-13
Abstract
Epstein-Barr virus is one of the causes of known human cancers such as PLTD, BL and XLP. It is persistent in about 90% of the global population. Prevalent antiviral agents are not effective. A systematic review was undertaken to discuss current treatment options available for EBV infection. A search was made of PubMed to identify relevant papers published from 2000 to 2010 using various search indexes. The review is based on 11 articles included in the study. The result showed that there is no studies which analyzed antiviral agents in EBV infection. Combinational therapy using antiviral agents, immunotherapy and anticancer agents should be considered while antibiotic regimen should be considered to take care of any sepsis. Resistance to antiviral agents especially cross-resistance is burden in EBV infection Studies should be undertaken to evaluate resistance pattern in EBV infection. To assess the efficacy of EBV therapeutics. Viral load using molecular techniques should be used as biomarker of efficacy.Keywords
This publication has 27 references indexed in Scilit:
- Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virusAntiviral Research, 2010
- Spectrum of Epstein-Barr virus-related diseases: a pictorial reviewJapanese Journal of Radiology, 2009
- The Antiherpetic Drug Acyclovir Inhibits HIV Replication and Selects the V75I Reverse Transcriptase Multidrug Resistance MutationJournal of Biological Chemistry, 2008
- Acyclovir‐Resistant Corneal HSV‐1 Isolates from Patients with Herpetic KeratitisThe Journal of Infectious Diseases, 2008
- Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virusLiver Transplantation, 2008
- A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral targetJournal of Antimicrobial Chemotherapy, 2008
- Structure of the Epstein-Barr Virus Oncogene BARF1Journal of Molecular Biology, 2006
- Laboratory markers of tumor burden in nasopharyngeal carcinoma: A comparison of viral load and serologic tests for Epstein‐Barr virusInternational Journal of Cancer, 2004
- Antiviral drugs in current clinical useJournal of Clinical Virology, 2004
- Hepatitis B Virus Reactivation in a Case of Non-Hodgkin's Lymphoma Treated with Chemotherapy and Rituximab: Necessity of Prophylaxis for Hepatitis B Virus Reactivation in Rituximab TherapyLeukemia & Lymphoma, 2004